Abstract Submission Information

 

Abstract Submission Opens:

March 31, 2019

Abstract Submission Closes:

11:59 PM ET, Friday May 31, 2019

Notifications:

Mid-July, 2019

Withdrawal Deadline:

11:59 PM ET, Thursday August 1, 2019

 

The abstract submission portal is now closed.

 

All participants at the AMP 2019 Annual Meeting & Expo are invited to submit abstracts of original studies related to molecular pathology and diagnostics.

QUICK LINKS / RESOURCES
Eligibility
Submission Categories
Deadlines
Rules for Abstract Submission
Additional Information
Author Information
2019 Abstract Author Index (Coming Soon)
2019 Abstract Author Disclosures (Coming Soon)

Eligibility

Only AMP Regular Members are eligible to submit abstracts. Associate Members (Trainees) and non-members must have a Regular Member sponsor their abstract. The Regular Member does not need to be an author on the abstract. If you are not a Regular Member of AMP, join now to submit your abstract today. You may submit an abstract and apply to join AMP on the same day, up to and through the submission deadline. However, we encourage you to join AMP in advance of the deadline!

 

Submission Categories

  • Genetics
  • Hematopathology
  • Infectious Diseases
  • Informatics
  • Solid Tumors
  • Technical Topics
  • Other (e.g. Education)*

*Abstract submissions in the "Other (e.g. Education)" topic category may include descriptions of novel educational approaches, innovative programs, pioneering technologies, etc. As with other abstract submissions, these abstract submissions must demonstrate the scientific method, i.e., describe the methodology and data collection, identify how to measure, analyze, and report outcomes, and provide conclusions. All submitted abstracts will be reviewed with the same criteria (see below).

 

Deadlines

Submission: May 31, 2019 at 11:59 pm ET.  NO EXCEPTIONSThe final abstract submission step is not complete until you have clicked the "Save and Finalize" button. The Corresponding Author will receive a confirmation email, but only after the abstract has been successfully finalized and submitted. Abstracts that are in process but not finalized after the deadline will not be considered for acceptance and/or awards.

Notification: The Corresponding Author will be notified by email no later than mid-July. Accepted abstracts will be published in the November 2019 issue of The Journal of Molecular Diagnostics (JMD) (see "Eligibility for Publication" section). Abstracts that are not eligible for publication in JMD, i.e., have been submitted to another publication or to another meeting that occurs before November 2019, will be rejected. Abstracts may be withdrawn until 11:59 pm ET on August 1, 2019.

Embargo: The research presented as posters at the AMP Annual Meeting & Expo from the abstracts published in the November issue of JMD is embargoed until the first day of poster presentations at the Annual Meeting.

Poster Presentation: First authors of accepted abstracts are expected to register as attendees and present posters at the Annual Meeting & Expo summarizing their studies. All authors of abstracts must adhere to the AMP Scientific Integrity Policy.

 

Rules for Abstract Submissions

Note: Abstracts that are not submitted properly will receive an administrative reject and will not be reviewed.

  1. Abstracts must be submitted properly. The online system is a database, with data fields (title, author 1, author 2, author 3, etc.) that are used to generate the published abstracts. Therefore, pay careful attention to the submission instructions and to the submission process, including spelling, capitalization, author names, etc.

  2. All abstracts must include the required headers listed below; each header must be included in your text:
    • Introduction: a brief discussion of the background or rationale of the study and/or the question addressed
    • Methods: the experimental approach, materials, and methods used in the study
    • Results: the data and results obtained in the study
    • Conclusions: the conclusions and/or implications of the results

  3. Abstract Limits:
    • Number of authors: 30
    • Abstract Title: 200 characters (including spaces)
    • Abstract Content: 2800 characters (with spaces and including section headers)

  4. You may include formatting (e.g. italicizing genes), Greek letters and special symbols, e.g. °C (degree sign), superscripts, etc. Data must be reported in narrative format in the abstract submission. No tables, figures, or references should be included in the abstract. (NEW THIS YEAR: Abstracts for the AMP Annual Meeting and Expo will be published in the Journal of Molecular Diagnostics. To ensure that the meeting abstracts are the same format as journal abstracts, authors should save tables, figures, and references for their presentations and/or posters as well as for full manuscript submissions.)

  5. Only AMP Regular Members are eligible to submit abstracts. Associate Members and non-members must have a Regular Member sponsor their abstract. If you are not a Regular Member of AMP, join now to submit your abstract today. You may submit an abstract and apply to join AMP on the same day, up to and through the submission deadline. However, we encourage you to join AMP in advance of the deadline!

  6. Your abstract must be eligible for publication in The Journal of Molecular Diagnostics (JMD):

    • The same abstract submitted to the AMP Annual Meeting & Expo must not have been published elsewhere (including the web), submitted to another publication, or submitted to another meeting that occurs prior to the AMP Annual Meeting.
    • Abstracts that have been submitted to other meetings that occur earlier in the year should be revised, e.g., with additional data, before submitting to the AMP Annual Meeting.

  7. Your abstract will be rated using four criteria (NEW THIS YEAR: Abstracts for the AMP Annual Meeting and Expo will undergo blind review, i.e., the reviewers will not be able to see the names or the affiliations of the abstract author(s). Please refrain from including identifiers in the body of your abstract. The Program Committee will be able to see author and affiliation informatoin after review, during the assignment of platform presentations.):
    • Originality and Clarity
    • Novelty
    • Scientific Merit/Rigor
    • Appropriate Conclusions

  8. Summary: Grounds for abstract rejection are:
    • Failure to follow directions in 1-6.
    • The abstract is not eligible for publication in JMD.
    • The abstract contains no scientific data and/or has only a promise of future data.
    • Submission of duplicate abstracts.
    • A sponsor is not an AMP Regular member.
    • A sponsor or any author violated any of the AMP rules for presentation at a previous meeting, e.g., the authors failed to present a poster without notifying AMP prior to the meeting.
The five most common reasons for rejection are:
  • Previously presented/published data
  • Poor organization/clarity
  • No novel information
  • Insufficient scientific quality
  • Insufficient data
Additional reasons for administrative abstract rejection without review include:
  • The use of all capital letters in the title
  • Improper use of italics (i.e., genes should be italicized, not proteins)
  • Excessive violations of other guidelines in the style guide
  • Overt endorsement and/or promotion of a product or service
  • Submission of duplicate or highly replicative abstracts under different first author names

 

Additional Information

If you receive a character count error after submitting your abstract, please note the following:
This count error happens when there are hidden characters in the abstract’s text, which is not unusual if the text has been copied from somewhere else.  If the text is written from scratch in the submission box, the character count error is not likely.  We suggest entering text manually rather than copying and pasting the text from other documents.  Alternatively, you could also try copying the text of the abstract to Notepad first, then from Notepad to the submission form. This usually removes hidden and special characters.

You can begin and edit your abstract an unlimited number of times prior to the deadline by clicking “Save and Next” on the bottom of the submission pages. After you finalize your abstract prior to the deadline, click on the “Save and Finalize” button on the last page of the entry forms to complete your submission for review. Please note that:

  • The submission is not complete until you click “Save and Finalize” and
  • After “Save and Finalize” is clicked, no changes can be made.

Submission Deadline: May 31, 2019 at 11:59 pm ET.  NO EXCEPTIONSThe final abstract submission step is not complete until you have clicked the "Save and Finalize" button. The Corresponding Author will receive a confirmation email, but only after the abstract has been successfully finalized and submitted. Abstracts that are in process but not finalized after the deadline will not be considered for acceptance and/or awards.

Abstracts may be withdrawn until 11:59 pm ET on August 1, 2019.

Please visit the links below to read other information about the abstract submission process:

Upon entering the abstract submission system, do not use your Internet browser’s back button. Instead, click on the “Prev” button next to the “Save and Next” button at the bottom right of each form page.

 

Author Information

  1. The Corresponding (Submitting) Author is the individual who submits the abstract and is the contact person for all correspondence from AMP. The Corresponding Author does not need to be the senior author. The Corresponding Author has the following responsibilities and will:
    • Verify that all authors agree at the time of abstract submission that, if accepted, the abstract will be published in JMD.
    • Verify that all authors agree at the time of abstract submission to transfer all copyright ownership to the Association for Molecular Pathology and the American Society for Investigative Pathology should the abstract be accepted for publication in JMD.
    • Verify that all authors agree to, and any supervisors have given permission for, the presentation of a scientific poster at the annual meeting.
    • Be responsible for notifying all other authors of acceptance, rejection, scheduling and any other information provided by AMP.
    • Be responsible for notifying the Presenting (First) Author of the AMP Rules for Poster Display and any other information provided by AMP. Young Investigator Award applicants are responsible for notifying their faculty mentors of the additional rules for poster display for award (see Poster Presentation Schedule).
    • Be responsible for compliance with the AMP Scientific Integrity Policy.

  2. The First Author is also considered the Presenting Author (who may be the Corresponding Author), has the following responsibilities, and will:
    • Register for the Annual Meeting and attend the poster at the assigned time period to discuss the study and answer questions. If the Presenting Author is unable to attend the Annual Meeting to present the poster, every effort should be made to arrange for one of the other authors to present the poster. Both AMP and the Annual Meeting Program Chair, Dr. Lindeman must be notified.  Failure to defend one's study by not attending the poster during the assigned time period is a violation of the AMP Scientific Integrity Policy and may result in forfeiture of future abstract submission privileges.
    • Ensure that the abstract poster conforms to the Rules for Poster Display at the Annual Meeting (i.e., poster display size, format, and schedule).

  3. Please note that:
    1. The Association for Molecular Pathology (AMP) and the American Society for Investigative Pathology (ASIP) are the co-owners of JMD and own the copyright for all manuscripts and abstracts published in the journal.  The Corresponding (Submitting) author must verify at the time of abstract submission that, if the abstract is accepted, all authors agree to (1) publication of the abstract in JMD, and (2) transfer copyright ownership to AMP and ASIP. For US government employees, the above assignment applies only to the extent allowed by law. For more information on publication in JMD, please see this link.
    2. Accepted abstracts that have not been previously published as either an abstract or a paper will be eligible for publication in the November 2019 issue of JMD. Abstracts that have been previously published or that are under consideration as an abstract for another meeting that occurs prior to November 2019 will be rejected.

  4. IMPORTANT: A disclosure report of relevant financial relationships is required for each author of a submitted abstract. Therefore, we recommend that you collect disclosure information from each author before you begin your abstract submission in order to expedite the online entry process. Each time you add an author's name during the online submission process, you will be asked to complete a disclosure report that is specific to that author. Employees of commercial entities should disclose employment in this section. Noting the company name in the Author Information field is not sufficient.